Glynux M 1 Tablet is primarily indicated for the management of elevated blood glucose levels in individuals diagnosed with type 2 diabetes mellitus. This medication is categorised under the class of oral antidiabetic agents.
• Management of type 2 diabetes mellitus
• Stabilisation of blood glucose levels
• Mitigation of complications arising from prolonged hyperglycaemia, such as nephropathy and neuropathy
• Reduction in the risk of cardiovascular events, including myocardial infarction and cerebrovascular accidents
• Take the tablet whole, accompanied by a glass of water.
• Do not crush, break, or chew the tablet.
• Administer once daily, preferably with breakfast or the first substantial meal.
• Maintain the prescribed dosage and consult your doctor prior to any alterations.
• Discontinuation should only occur under medical advice.
This tablet is taken orally.
Glynux M 1 Tablet may induce certain side effects, including but not limited to:
• Diarrhoea
• Vomiting
• Nausea
• Altered taste
• Abdominal discomfort
Glynux M 1 Tablet comprises two active constituents:
• Glimepiride (1 mg): Classified under sulfonylureas, this component induces pancreatic beta-cell insulin secretion, thereby reducing circulating blood glucose.
• Metformin (500 mg): Belonging to the biguanide category, metformin diminishes hepatic glucose production and augments peripheral insulin sensitivity, facilitating more effective utilisation of insulin.
This medicine is contraindicated during pregnancy.
This medicine is not recommended during breastfeeding.
Abstain from alcohol to prevent exacerbation of adverse effects.
Notify your doctor of any hepatic conditions before commencing treatment.
Consultation with your doctor is necessary if renal impairment is present to assess medication suitability.
Be vigilant, as this medication may impair cognitive and motor functions.
Avoid use if allergic to glimepiride, metformin, or any excipients in the formulation.
Caution is advised; consult a doctor for individuals under 18 years of age.
Utilise under medical guidance, particularly for those over 70, due to heightened sensitivity to adverse reactions.
Drug-Drug Interactions
• Sulfonylureas: Concurrent use may potentiate hypoglycaemia.
• ACE Inhibitors: These may amplify the glucose-lowering effect, increasing hypoglycaemic risk.
Drug-Food Interactions
• High Carbohydrate Foods: May decrease the efficacy of blood glucose control.
Drug-Disease Interactions
• Type 1 Diabetes: Ineffective for individuals with this condition due to the absence of endogenous insulin production.
Daily Dosage
• This tablet is to be taken as directed by your doctor, tailored to individual health conditions and response to treatment.
Missed Dose
• If a dose is missed, take it promptly when remembered. If proximate to the subsequent scheduled dose, forego the missed dose. Do not double the dosage.
Overdose
• Symptoms of overdose may include nausea, diarrhoea, or gastric distress. Should symptoms persist, seek immediate medical attention.
• Store at room temperature, not exceeding 30°C.
• Preserve it in its original packaging to protect it from moisture and light.
• Avoid exposure to excessive heat or cold.
• Adhere to a diet minimal in sugars and refined carbohydrates.
• Incorporate regular physical activity, such as moderate-intensity exercise, to enhance glycaemic control.
.avif)
%20(1).png)
.webp)